Thus, treatment with ezetimibe reduced weight gain and plasma TG levels in Pemt+/+ mice, but worsened mRNA markers for NAFLD in mice lacking PEMT. The gene discussed is PEMT; the disease is metabolic dysfunction-associated steatotic liver disease.